Neo Ivy Capital Management Blueprint Medicines Corp Transaction History

Neo Ivy Capital Management

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 15, 2023	SELL	$42.2 - $66.37 $65,578 - $103,138	-1,554 Reduced 30.65%	3,516 $222,000
Q4 2022 Mar 24, 2023	BUY	$41.06 - $66.48 $105,031 - $170,055	2,558 Added 101.83%	5,070 $222,000
Q3 2022 Nov 15, 2022	BUY	$49.93 - $77.7 $125,424 - $195,182	2,512 New	2,512 $166,000
Q1 2021 Oct 07, 2021	SELL	$90.71 - $108.28 $38,914 - $46,452	-429 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$92.08 - $124.48 $39,502 - $53,401	429 New	429 $48,000
Q3 2020 Nov 17, 2020	SELL	$66.45 - $92.7 $199 - $278	-3 Closed	0 $0
Q2 2020 Aug 17, 2020	BUY	$57.09 - $79.27 $171 - $237	3 New	3 $0
Q3 2019 Nov 21, 2019	SELL	$72.9 - $101.41 $218 - $304	-3 Closed	0 $0
Q2 2019 Aug 15, 2019	BUY	$73.54 - $97.8 $220 - $293	3 New	3 $0

351

60.3M

2.25M

1.18M

Ticker BPMC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,719,600
Market Cap $5.4B
Description
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...

Get notified when there are updates to the investment portfolio of Neo Ivy Capital Management, based on Form 13F filings with the SEC.

Stay updated on Neo Ivy Capital Management with notifications on news.